Bruce Reidenberg

USPTO Granted Patents = 11 (Patent Applications = 13)

CIPO Patents = 2 (Patent Applications = 7)

EPO Patents = 5 (Patent Applications = 11)

Average Co-Inventor Count = 2.1

ph-index = 4

Forward Citations = 39(Granted Patents)

Company Filing History:

Years Active: 2006-2024

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12053478 - Taurultam, taurinamide and methylene glycol treatment for MYC—expressing tumors in mammalian bodies (2024-08-06),

2. 12016865 - Methods and pharmaceutical compositions for treating candida auris in blood (2024-06-25),

3. 11541061 - Neuroblastoma treatment with taurolidine hydrolysis products (2023-01-03),

4. 10973815 - Delta opioid agonist mu opioid antagonist compositions and methods for treating Parkinsons disease (2021-04-13),

5. 10478640 - Field sterilizer and vascular connector kit (2019-11-19),

6. 8790689 - Tamper resistant transdermal dosage form (2014-07-29),

7. 8778382 - Tamper resistant transdermal dosage form (2014-07-15),

8. 8637073 - Treatment of dependence withdrawal (2014-01-28),

9. 7413748 - Transdermal buprenorphine to treat pain in sickle cell crisis (2008-08-19),

10. 7270830 - Transdermal buprenorphine dosage regimen for analgesia (2007-09-18),

11. 7125884 - N-but-3-enyl norbuprenorphine and its use as analgesic (2006-10-24),

Title: Bruce Reidenberg: Innovator in Cancer Treatment

Introduction

Bruce Reidenberg is a notable inventor based in Rye, NY (US), recognized for his contributions to medical science, particularly in cancer treatment. He holds a total of 11 patents, showcasing his innovative approach to addressing complex health issues.

Latest Patents

Among his latest patents, Reidenberg has developed methods for treating MYC-expressing tumors in mammalian bodies. His work includes a composition that combines taurultam, taurinamide, and methylene glycol, aimed at effectively treating cancers that overexpress N-myc, C-myc, and L-myc genes. Additionally, he has patented methods and pharmaceutical compositions for treating Candida auris in blood, utilizing taurolidine and its derivatives to achieve effective treatment.

Career Highlights

Reidenberg has made significant strides in his career, working with reputable companies such as Purdue Pharma L.P. and Cormedix Inc. His experience in these organizations has contributed to his expertise in pharmaceutical innovations and cancer therapies.

Collaborations

Throughout his career, Reidenberg has collaborated with esteemed colleagues, including Robert DiLuccio and Daniel A. Spyker. These partnerships have further enhanced his research and development efforts in the medical field.

Conclusion

Bruce Reidenberg's innovative work in cancer treatment and his impressive portfolio of patents highlight his dedication to improving healthcare solutions. His contributions continue to impact the medical community positively.

This text is generated by artificial intelligence and may not be accurate.